Chidamide and Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Study
Latest Information Update: 30 Nov 2021
At a glance
- Drugs Sintilimab (Primary) ; Tucidinostat (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 22 Nov 2021 Status changed from not yet recruiting to recruiting.
- 15 Nov 2021 New trial record